Iqbal Ike K. Ahmed, MD, FRCSC, Nathan M. Radcliffe, MD; I. Paul Singh, MD; Mahmoud A. Khaimi, MD; Mark J. Gallardo, MD; and David Richardson, MD, discuss the the misconceptions surrounding selective laser trabeculoplasty (SLT), safety and efficacy of SLT and highlight the advantages of minimizing the medication burden for patients.
At ASCRS 2018 in Washington, DC, a group of surgeons experienced in interventional glaucoma therapies sat down to discuss the roles of selective laser trabeculoplasty (SLT) and microinvasive glaucoma surgery (MIGS) for treatment of open angle glaucoma (OAG).
Laser Trabeculoplasty has a long track record of effectively lowering the IOP while presenting relatively low risk to those receiving this treatment. Selective Laser Trabeculoplasty has two key advantages over Argon Laser Trabeculoplasty: (1) it is repeatable;
